{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:43:03Z","timestamp":1758613383428,"version":"3.44.0"},"reference-count":124,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2025,9,2]]},"DOI":"10.1080\/17425255.2025.2538885","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:48:26Z","timestamp":1753336106000},"page":"1059-1070","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Clinical considerations on the use of antiretrovirals and renal impairment"],"prefix":"10.1080","volume":"21","author":[{"given":"Christopher","family":"Livesay","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy","place":["Memphis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kubwayo Kayihura","family":"Mike","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy","place":["Memphis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karissa","family":"Grey","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy","place":["Memphis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore James","family":"Cory","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy","place":["Memphis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 fact sheet 2024. 2024. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200208160-00012"},{"key":"e_1_3_4_5_1","unstructured":"Centers for Disease Control and Prevention. HIV Surveillance report: diagnoses deaths and prevalence of HIV in the United States and 6 territories and freely associated States 2022. HIV Surveillance Report. https:\/\/www.cdc.gov\/hiv-data\/nhss\/hiv-diagnoses-deaths-prevalence.html"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318134257a"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000243"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081254"},{"issue":"1","key":"e_1_3_4_9_1","article-title":"CfDCa. Estimated HIV incidence and prevalence in the United States, 2018\u20132022","volume":"29","author":"Prevention","year":"2024","unstructured":"Prevention. CfDCa. Estimated HIV incidence and prevalence in the United States, 2018\u20132022. HIV Surveillance Supplemental Report. 2024;29(1).","journal-title":"HIV Surveillance Supplemental Report"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1545109710384505"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2254-7"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06962-3"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/424013"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00232.x"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.01.448"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66532-w"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12122645"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-522"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000112851"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00693.x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01036.x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.9"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.007"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200304110-00026"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu919"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/523729"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(95)94706-8"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.12.2855"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000046045"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2920"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1451667"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac126"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.02.003"},{"key":"e_1_3_4_34_1","unstructured":"U.S. Food and Drug Administration. Bristol-myers Squibb company. Sustiva (efavirenz). [Package insert]. 2011 [cited 2025 Jan 10]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020972s038lbl.pdf"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.049601"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e011f"},{"key":"e_1_3_4_37_1","unstructured":"Janssen Therapeutics. Division of Janssen products LP. Intelence (etravirine) [package insert]: U.S. Food and Drug administration. 2012 [cited 2025 Jan 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022187s009lbl.pdf"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61047-2"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328328f79d"},{"key":"e_1_3_4_40_1","unstructured":"U.S. Food and Drug Administration. Tibotec pharmaceuticals. Edurant (rilpivirine). [Package insert]. 2011 [cited 2025 Jan 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202022s000lbl.pdf"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60983-5"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01421-13"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.00087.2012"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004071"},{"key":"e_1_3_4_45_1","unstructured":"Janssen Pharmaceuticals. Prezista (darunavir). [Package insert]: u.S. Food and Drug administration. 2011 [cited 2025 Jan 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021976s021lbl.pdf"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab001"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328347f40d"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.01.014"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt125"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz369"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834a1cd6"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001353"},{"key":"e_1_3_4_53_1","unstructured":"ViiV Healthcare. Vocabria (cabotegravir) [Package insert]: U.S. Food and drug Administration. 2021 [cited 2025 Jan 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212887s000lbl.pdf"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.664"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003567"},{"key":"e_1_3_4_56_1","unstructured":"ViiV Healthcare. Tivicay (dolutegravir) [Package insert]: U.S. Food and drug Administration. 2013 [cited 2025 Jan 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204790lbl.pdf"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1590-9"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03131-15"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-024-00616-5"},{"key":"e_1_3_4_60_1","unstructured":"Merck Sharp & Dohme Corp. Isentress (raltegravir) [package insert]: U.S. Food and Drug administration. 2013 [cited 2025 Jan 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022145s029lbl.pdf"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016196"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00363-10"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001012"},{"key":"e_1_3_4_64_1","unstructured":"Gilead Sciences. Inc. Biktarvy (bictegravir emtricitabine and tenofovir alafenamide) [package insert]: U.S. Food and Drug administration. 2018 [cited 2025 Jan 29]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210251s000lbl.pdf\\"},{"key":"e_1_3_4_65_1","unstructured":"Gilead Sciences Inc. Biktarvy (bictegravir emtricitabine and tenofovir alafenamide) [package insert]: U.S. Food and Drug administration. 2018 [cited 2025 Jan 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210251s000lbl.pdf"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1188"},{"key":"e_1_3_4_67_1","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral Agents in adults and adolescents with HIV. Department of health and human services. 2024. Available at [cited 2025 Jan 17]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv Appendix B Table 12."},{"key":"e_1_3_4_68_1","unstructured":"Gilead Sciences. Inc. Sunlenca (lenacapavir) [package insert]: U.S. Food and Drug administration. 2022 [cited 2025 Jan 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215973s000lbl.pdf"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01328-1"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01344-23"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8865265"},{"key":"e_1_3_4_72_1","unstructured":"Roche Laboratories Inc. & Trimeris Inc. Fuzeon (enfuvirtide) [package insert]: U.S. Food and Drug administration. 2003 [cited 2025 Jan 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021481s032lbl.pdf"},{"key":"e_1_3_4_73_1","unstructured":"Gilead Sciences. Inc. Emtriva (emtricitabine) [Package insert]: u.S. Food and Drug administration. 2007 [cited 2025 Jan 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021500s010 021896s004lbl.pdf"},{"key":"e_1_3_4_74_1","unstructured":"Gilead Sciences. Inc. Truvada (emtricitabine\/tenofovir disoproxil fumarate) [package insert]: U.S. Food and Drug administration. 2013 [cited 2025 Jan 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021752s035lbl.pdf"},{"key":"e_1_3_4_75_1","unstructured":"Gilead Sciences Inc. Descovy (emtricitabine and tenofovir alafenamide) [package insert]: U.S. Food and Drug administration. 2019 [cited 2025 Jan 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208215s012lbl.pdf"},{"key":"e_1_3_4_76_1","unstructured":"Gilead Sciences. Inc. Odefsey (emtricitabine ripilvirine and tenofovir alafenamide) [package insert]: U.S. Food and Drug administration. 2018 [cited 2025 Jan 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208351s006lbl.pdf"},{"key":"e_1_3_4_77_1","unstructured":"Janssen Therapeutics Division of Janssen Products LP. Symtuza. (darunavir cobicistat emtricitabine and tenofovir alafenamide) [Package insert]: U.S. Food and Drug administration. 2018 [cited 2025 Jan 30]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210455s000lbl.pdf"},{"key":"e_1_3_4_78_1","unstructured":"Gilead Sciences. Inc. Genvoya (elvitegravir cobicistat emtricitabine and tenofovir alafenamide) [package insert]: U.S. Food and Drug administration. 2022 [cited 2025 Jan 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207561s029lbl.pdf"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02058-13"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.4.507"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000908"},{"key":"e_1_3_4_82_1","unstructured":"ViiV Healthcare. Epivir (lamivudine) [package insert]: U.S. Food and Drug administration. 2017 [cited 2025 Jan 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020564s37_020596s036lbl.pdf"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199212000-00008"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00044.x"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1514"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy225"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462418800865"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu617"},{"key":"e_1_3_4_89_1","unstructured":"Gilead Sciences. Inc. Viread (tenofovir disoproxil fumarate) [Package insert]: U.S. Food and Drug administration. 2012 [cited 2025 Jan 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022577lbl.pdf"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu617"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2016.02.013"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-011-0310-6"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200403010-00007"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1086\/368314"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283262a64"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833202e2"},{"key":"e_1_3_4_97_1","unstructured":"Mylan Specialty LP. Cimduo (lamivudine and tenofovir disoproxil fumarate) [package insert]: U.S. Food and Drug administration. 2018 [cited 2025 Jan 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/pepfar\/022141PI.pdf"},{"key":"e_1_3_4_98_1","unstructured":"Gilead Sciences. Inc. Tybost (cobicistat) [Package insert]: U.S. Food and Drug administration. 2017 [cited 2025 Jan 29]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203094s008lbl.pdf"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832c96e9"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1086\/524061"},{"key":"e_1_3_4_101_1","unstructured":"Gilead Sciences. Inc. Vemlidy (tenofovir alafenamide) [package insert]: U.S. Food and Drug administration. 2022 [cited 2025 Jan 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208464s014lbl.pdf"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2770"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1898-1906.2005"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182965d45"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005146"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002223"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_3_4_108_1","unstructured":"Bristol-myers Squibb company. Reyataz (atazanavir sulfate) [package insert]: U.S. Food and Drug administration. 2011 [cited 2025 Jan 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021567s026lbl.pdf"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit043"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis621"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19514"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0056-4"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1086\/499048"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002516"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182645648"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"e_1_3_4_117_1","unstructured":"Pfizer Labs. Selzentry (maraviroc) [Package insert]: u.S. Food and Drug administration. 2007 [cited 2025 Jan 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022128lbl.pdf"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1403-99"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1391"},{"key":"e_1_3_4_120_1","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral Agents in adults and adolescents with HIV Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-combination?view=full"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00701-8"},{"issue":"3","key":"e_1_3_4_122_1","first-page":"161","article-title":"HIV-Associated complications: a systems-based approach","volume":"96","author":"Chu C","year":"2017","unstructured":"Chu C, Pollock LC, Selwyn PA. HIV-Associated complications: a systems-based approach. Am Fam Physician. 2017;96(3):161\u2013169.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462418816785"},{"key":"e_1_3_4_124_1","unstructured":"Centers for Disease Control and Prevention. HIV Surveillance report: diagnoses of HIV infection in the United States and dependent areas 2021. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/149071"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000589"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.04.021"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2025.2538885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T06:38:32Z","timestamp":1758609512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2025.2538885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":124,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"alternative-id":["10.1080\/17425255.2025.2538885"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2025.2538885","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"type":"print","value":"1742-5255"},{"type":"electronic","value":"1744-7607"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}